Okomera specializes in automated 3D organoid screening technology that accelerates access to improved, precision-based cancer therapies. Their goal is to advance personalized medicine by providing healthcare actors with powerful tools to analyze how tumors respond to various therapies. 

Okomera integrates standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.

They have developed a miniaturized 3D assay to help clinical decision. Using a biopsy of the tumor, Okomera’s cell culture technology includes: a fluidic machine, reagents, and a software analysis designed to estimate and identify the best drug treatment for each cancer patient.

– Therapeutic areas: Oncology, Assays on chip, Drug discovery

– Based in: Paris (FRANCE)
Berkeley (US)

– Employees: 11 – 50

– Created in: 2020